0001415889-24-024076.txt : 20240927 0001415889-24-024076.hdr.sgml : 20240927 20240927193152 ACCESSION NUMBER: 0001415889-24-024076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240927 FILED AS OF DATE: 20240927 DATE AS OF CHANGE: 20240927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DiRaimondo Thomas CENTRAL INDEX KEY: 0002005618 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40475 FILM NUMBER: 241336279 MAIL ADDRESS: STREET 1: C/O JANUX THERAPEUTICS, INC. STREET 2: 10955 VISTA SORRENTO PARKWAY, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 751-4493 MAIL ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-09272024_110948.xml X0508 4 2024-09-27 0001817713 Janux Therapeutics, Inc. JANX 0002005618 DiRaimondo Thomas C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 false true false false Chief Scientific Officer 1 Common Stock 2024-09-27 4 S 0 4325 46.2057 D 98613 D Common Stock 2024-09-27 4 S 0 675 47.2245 D 97938 D The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024. The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ James Pennington, Attorney-in-Fact 2024-09-27